{"id":716586,"date":"2010-04-14T08:43:14","date_gmt":"2010-04-14T12:43:14","guid":{"rendered":"tag:www.hepatitis-central.com,2010:\/mt\/\/1.807"},"modified":"2010-04-14T08:46:35","modified_gmt":"2010-04-14T12:46:35","slug":"telaprevirs-efficacy-against-hepatitis-c-trumps-standard-treatment","status":"publish","type":"post","link":"https:\/\/mereja.com\/index\/716586","title":{"rendered":"Telaprevir&#8217;s Efficacy Against Hepatitis C Trumps Standard Treatment"},"content":{"rendered":"<p>Results of the PROVE3 trial found that drug regimens using telaprevir were more effective against Hepatitis C than regimens without telaprevir in both treatment na\u00efve patients and previous treatment non-responders.<\/p>\n<p>Mid-stage trial notes efficacy in investigational hepatitis C treatment<\/p>\n<p>By Alaric DeArment<\/p>\n<p>CORK, Ireland (Apr. 9) Patients with chronic genotype 1 hepatitis C fared better when given an investigational drug developed by Johnson &#038; Johnson division Tibotec and Vertex Pharmaceuticals than when given the standard therapy, after they had failed previous treatments, according to results of a mid-stage trial published Thursday.<\/p>\n<p>The results of the 453-patient, phase 2 &#8220;PROVE3&#8221; trial, published in the New England Journal of Medicine, found that regimens based on the drug telaprevir worked better than other drugs at keeping the virus undetectable in the bloodstream. <\/p>\n<p>Continue reading this entire article:<br \/>\n<a href=\"http:\/\/drugstorenews.com\/story.aspx?id=136035&#038;menuid=345\">http:\/\/drugstorenews.com\/story.aspx?id=136035&#038;menuid=345<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Results of the PROVE3 trial found that drug regimens using telaprevir were more effective against Hepatitis C than regimens without telaprevir in both treatment na\u00efve patients and previous treatment non-responders. Mid-stage trial notes efficacy in investigational hepatitis C treatment By Alaric DeArment CORK, Ireland (Apr. 9) Patients with chronic genotype 1 hepatitis C fared better [&hellip;]<\/p>\n","protected":false},"author":288,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[4821],"tags":[],"class_list":["post-716586","post","type-post","status-publish","format-standard","hentry","category-news"],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p9NivD-30pQ","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/716586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/users\/288"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/comments?post=716586"}],"version-history":[{"count":0,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/716586\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/media?parent=716586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/categories?post=716586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/tags?post=716586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}